Meeting
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
Authors
Zhengfu Fan
Peking University Cancer Hospital and Institute, Beijing, China
Zhengfu Fan , Jin Wang , Meiyu Fang , Jilong Yang , Yun Yang , Jifang Gong , Qiuying Ma , Jinming Han , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04390737
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11562)
DOI
10.1200/JCO.2023.41.16_suppl.11562
Abstract #
11562
Poster Bd #
496
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan
Poster
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
First Author: Mrinal M. Gounder
Poster
2020 ASCO Virtual Scientific Program
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
First Author: Marjorie Glass Zauderer